口服普萘洛尔治疗婴幼儿眶周血管瘤临床疗效观察

中国口腔颌面外科杂志 ›› 2016, Vol. 14 ›› Issue (2): 140-143.

口服普萘洛尔治疗婴幼儿眶周血管瘤临床疗效观察

薛雷, 刘子玫, 徐大朋, 佟爽, 程晨, 宫贺, 王绪凯

中国医科大学口腔医学院口腔颌面外科;辽宁省口腔医学研究所口腔颌面外科研究室,辽宁沈阳 110002

收稿日期:2015-03-03 出版日期:2016-03-20 发布日期:2016-04-06
通讯作者: 王绪凯,Tel:024-22892451,E-mail:wangxukai757892@sina.com
作者简介:薛雷(1981-),男,博士,E-mail:xuelei4970362@sina.com
基金资助:
辽宁省教育厅资助项目(2009A747)

Oral propranolol for treatment of periorbital infantile hemangiomas

XUE Lei, LIU Zi-mei, XU Da-peng, TONG Shuang, CHENG Chen, GONG He, WANG Xu-kai

Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University;Liaoning Institute of Dental Research. Shenyang 110002, Liaoning Province, China

Received:2015-03-03 Online:2016-03-20 Published:2016-04-06

摘要/Abstract

摘要： 目的:评价口服普萘洛尔治疗婴幼儿眶周血管瘤的临床疗效与安全性。方法:2012年5月—2014年1月,30例婴幼儿眶周血管瘤患儿接受并完成口服普萘洛尔治疗。其中男10例,女20例;年龄2~13个月,平均4.8个月。服药剂量1.0~1.5 mg/kg,每天1次顿服。治疗时间4~38周,平均疗程19周。第1次复诊为2周,以后每个月复诊1次,定期拍照、记录血管瘤的颜色、质地、大小变化,观察并及时处理治疗期间的不良反应,按4级评分法对疗效进行评价。结果:随访3~10个月,疗效评定结果Ⅰ级(差)0例,Ⅱ级(中)2例,Ⅲ级(好)9例,Ⅳ级(优)19例。所有患儿服药30 min后均出现心率减慢,血压降低,2 h后达高峰,12 h后恢复正常,无任何临床症状。4例患儿出现轻度腹泻,1例出现睡眠改变,未见严重不良反应。结论:口服普萘洛尔治疗婴幼儿眶周血管瘤起效快,疗效显著,耐受性好,不良反应轻微,可作为首选治疗方法。

关键词: 血管瘤, 普萘洛尔, 眶周

Abstract: PURPOSE: To assess the efficacy and safety of propranolol in the management of periorbital infantile hemangiomas. METHODS: Between May 2012 and January 2014, oral propranolol was applied to 30 infants with periorbital hemangiomas at a dose of 1.0-1.5 mg/kg taken once daily. There were 10 males and 20 females aging from 2 to 13 months with a mean age of 4.8 months. The mean duration of treatment was 19 weeks (4 to 38 weeks). The first follow-up visit was performed 2 weeks after therapy and scheduled monthly thereafter. The changes of the tumor size, texture and color were monitored and recorded at a regular interval. The adverse effects after medication were observed and managed accordingly. The treatment response based on improvement in volume, color, and texture after treatment was classified using a 4-point scale system. RESULTS: All patients were followed up from 3 to 10 months. The overall response was scaleⅠ (poor) in 0 patient,scale Ⅱ(moderate) in 2 patients,scale Ⅲ (good) in 9 patients, and scale Ⅳ(excellent) in 19 patients. In all 30 infants, heart rates and blood pressure decreased 30 minutes post-medication and reached the peak within 2 hours. However, all these signs disappeared after taking propranolol for more than 12 h, and none required special treatment. Other side effects were observed in four patients involving diarrhea and one concerning sleep change. CONCLUSIONS: Oral propranolol was an effective and safe treatment for infantile periorbital hemangiomas, particularly early intervention suitable for severe periorbital proliferating infantile hemangiomas.

Key words: Hemangiomas, Propranolol, Periorbital region

中图分类号:

R739.8

薛雷, 刘子玫, 徐大朋, 佟爽, 程晨, 宫贺, 王绪凯. 口服普萘洛尔治疗婴幼儿眶周血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2016, 14(2): 140-143.

XUE Lei, LIU Zi-mei, XU Da-peng, TONG Shuang, CHENG Chen, GONG He, WANG Xu-kai. Oral propranolol for treatment of periorbital infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2016, 14(2): 140-143.

参考文献

[1] Shah S, Frieden IJ. Treatment of infantile hemangiomas with beta-blockers: a review [J]. Skin Therapy Lett, 2013,18(6): 5-7.
[2] De Graaf M, Breur JM, Raphaēl MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants [J]. J Am Aead Dermatol, 2011, 65(2): 320-327.
[3] 赵忠芳, 吕仁荣, 张健, 等. 口服普萘洛尔治疗眶周部增生期婴幼儿血管瘤 [J]. 中华整形外科杂志, 2011, 27(3): 174-177.
[4] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[5] Waner M, Suen JY. Management of congenital vascular lesions of the head and neck [J]. Oncology (Williston Park), 1995, 9(10): 989-994.
[6] Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment [J]. Pediatrics, 2006, 118(3): 882-887.
[7] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[8] Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy：risks and recommendations[J]. Pediatr Dermatol, 2009, 26(5): 610-614.
[9] 叶肖肖, 金云波, 林晓曦, 等. 外用马来酸噻吗洛尔治疗婴幼儿眼周浅表血管瘤的前瞻性研究 [J].中华整形外科杂志, 2012, 28(3): 161-164.
[10] Waner M, O TM. The role of surgery in the management of congenital vascular anomalies[J]. Tech Vasc Interv Radiol, 2013, 16(1): 45-50.
[11] 郑家伟, 马坤宁, 张凌. 婴幼儿血管瘤药物治疗概述 [J]. 中国口腔颌面外科杂志, 2014, 12(1): 1-6.
[12] 薛雷. 血管瘤发病机制及治疗前景展望 [J].中国实用口腔科杂志, 2010, 3(10): 632-635.
[13] Zimmermann AP, Wiegand S, Weruer JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature [J]. Int J Pediatr Otorhinolaryngol, 2010, 74(4): 338-342.
[14] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action [J]. Br J Dermatol, 2010, 163(2): 269-274.
[15] 郑家伟,张凌,陈正岗.普萘洛尔治疗婴幼儿血管瘤专家共识 [J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.